BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn (PRNewswire) - May 20, 2024 - P3 | N=196 | NCT03280056 | Sponsor: Brainstorm-Cell Therapeutics | "BrainStorm Cell Therapeutics Inc...will present new biomarker data suggesting that ALS patients may benefit from longer-term treatment with debamestrocel (NurOwn)...Recently published NfL data from the Phase 3 trial showed that participants treated with NurOwn had an 11% decline from baseline in NfL...The new EAP data to be presented at the ALS Summit showed that, for participants randomized to NurOwn, there was a 4% decrease from baseline in NfL in Phase 3 and a 27% and 36% decrease from baseline, at the ends of Period 1 and Period 2 of the EAP, respectively. These results suggest continual benefit from extended treatment of NurOwn."
Biomarker • P3 data • Amyotrophic Lateral Sclerosis • CNS Disorders
|